Continuous liquid interface production of 3D printed drug-loaded spacers to improve prostate cancer brachytherapy treatment

Hagan, C. Tilden; Bloomquist, Cameron; Kim, Isaiah; Knape, Nicole M.; Byrne, James D.; Tu, Litao; Wagner, Kyle; Mecham, Sue J.; DeSimone, Joseph M.; Wang, Andrew Z.

doi:10.1016/j.actbio.2022.06.023

Cited by 4 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hagan et al used continuous liquid interface production to construct 3D-printed drug-loaded brachytherapy spacers with varying surface patterns to regulate drug release. Using a mouse model of prostate cancer, they investigated these spacers using dexamethasone and docetaxel as model medicines and discovered that the application of drug-loaded spacers increased the efficacy of brachytherapy and did not seem to result in any systemic risk [ 138 ].…”

Section: Prostate Cancer Treatment By Novel Drug Delivery Systemmentioning

confidence: 99%

Emerging Trends of Nanomedicines in the Management of Prostate Cancer: Perspectives and Potential Applications

Deshmukh,

Singh,

Harwansh

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Prostate cancer is one of the most life-threatening disorders that occur in males. It has now become the third most common disease all over the world, and emerging cases and spiking mortality rates are becoming more challenging day by day. Several approaches have been used to treat prostate cancer, including surgery, radiation therapy, chemotherapy, etc. These are painful and invasive ways of treatment. Primarily, chemotherapy has been associated with numerous drawbacks restricting its further application. The majority of prostate cancers have the potential to become castration-resistant. Prostate cancer cells exhibit resistance to chemotherapy, resistance to radiation, ADT (androgen-deprivation therapy) resistance, and immune stiffness as a result of activating tumor-promoting signaling pathways and developing resistance to various treatment modalities. Nanomedicines such as liposomes, nanoparticles, branched dendrimers, carbon nanotubes, and quantum dots are promising disease management techniques in this context. Nanomedicines can target the drugs to the target site and enhance the drug’s action for a prolonged period. They may also increase the solubility and bioavailability of poorly soluble drugs. This review summarizes the current data on nanomedicines for the prevention and treatment of prostate cancer. Thus, nanomedicine is pioneering in disease management.

show abstract

Section: Prostate Cancer Treatment By Novel Drug Delivery Systemmentioning

confidence: 99%